Blood & Lymphoreticular

Anemia of chronic disease: differentiating and management

Clinical Overview and When to Suspect Anemia of Chronic Disease

— Blocks ferroportin on enterocytes and macrophages → traps iron in storage, reduces GI absorption

— Suppresses erythropoietin production and blunts marrow response to EPO

— Shortens RBC lifespan modestly (90–120 → 70–80 days)

— Mild-to-moderate normocytic anemia (Hgb typically 8–10 g/dL, rarely <8) in a patient with a known chronic inflammatory, infectious, or malignant condition

— Underlying conditions: rheumatoid arthritis, SLE, IBD, CKD, CHF, chronic infections (TB, osteomyelitis, HIV, endocarditis), malignancy, obesity, aging

— Indolent course; anemia parallels disease activity

Board pearl: A patient with rheumatoid arthritis on methotrexate with Hgb 9.5, MCV 86, low serum iron, low TIBC, elevated ferritin (>100) → anemia of inflammation. If ferritin is <30 or transferrin saturation <20% with high TIBC → coexisting iron deficiency demanding GI evaluation.

Step 3 management anchor: Don't reflexively transfuse or start IV iron — first identify and treat the underlying inflammatory driver. ACD often improves with disease control alone. Workup for occult blood loss is mandatory if iron studies suggest coexisting IDA, particularly in adults >50.

Anemia of chronic disease (ACD), now preferred term anemia of inflammation (AI), is the second most common anemia worldwide after iron deficiency and the most common anemia in hospitalized patients.

Driven by hepcidin upregulation via IL-6 (and other cytokines: TNF-α, IFN-γ), which:

When to suspect on Step 3:

Hgb floor: ACD alone rarely drops Hgb <8 g/dL — if lower, suspect a second process (bleeding, hemolysis, true iron deficiency, marrow infiltration).

MCV is usually normocytic (~75%), microcytic in ~25% (chronic, severe inflammation) — overlaps with IDA, the principal differential.

Reticulocyte count is inappropriately low for the degree of anemia (hypoproliferative).

Presentation Patterns and Key History

— Fatigue, exertional dyspnea, decreased exercise tolerance

— Pallor, occasional palpitations, worsening angina or claudication in patients with baseline CAD/PAD

— Cognitive slowing or worsened functional status in elderly

— RA: morning stiffness, symmetric small-joint pain

— SLE: rash, serositis, photosensitivity

— IBD: chronic diarrhea, abdominal pain, weight loss

— CKD: prior elevated creatinine, hypertension, diabetes

— CHF: orthopnea, PND, edema (note: ACD coexists in 30–50% of CHF)

— Malignancy: B-symptoms, unexplained weight loss, new lymphadenopathy

— Chronic infection: indolent fevers, drainage, prosthetic joint, IVDU

— Duration of anemia — chronic, indolent over months

— Bleeding history: menses (premenopausal women), melena, hematochezia, hematuria, epistaxis — points away from pure ACD

— Diet: vegetarian, alcohol use, restricted intake — points to nutritional deficiency overlay

— Medications: NSAIDs (GI loss), PPIs (impair iron/B12 absorption), methotrexate, AZT, chemotherapy

— Family history: thalassemia trait (can mimic microcytic ACD), hereditary anemias

— Travel/exposure: TB, malaria, parasites

Key distinction: Patients with isolated ACD typically lack pica, restless legs, koilonychia, or glossitis (suggest iron deficiency) and lack neuropathy or gait ataxia (suggest B12 deficiency). Presence of these symptoms in a patient with chronic disease implies a second mechanism is operating — don't anchor on ACD.

Board pearl: Onset of anemia within weeks of starting a new inflammatory flare (e.g., RA exacerbation, active diverticulitis) supports inflammation-driven anemia rather than chronic blood loss.

Symptoms are typically mild because anemia develops gradually, allowing physiologic compensation:

No symptoms specific to ACD itself — clinical clues come from the underlying disease:

Key history questions (Step 3 pattern recognition):

Functional decline in older adults is often the presenting clue rather than overt anemia symptoms — anemia in the elderly is never normal aging and warrants workup.

Physical Exam Findings and Hemodynamic Assessment

— Conjunctival/palmar pallor (Hgb usually <9–10 g/dL before detectable)

— Resting tachycardia, wide pulse pressure, flow murmur (systolic, soft) — signs of compensatory high-output state

— Hypotension or orthostasis → suggests acute bleeding overlay, not pure ACD

— Tachypnea, hypoxia → consider concurrent decompensation

— Rheumatologic: synovitis, ulnar deviation, swan-neck deformities (RA); malar rash, oral ulcers (SLE); sausage digits (psoriatic)

— GI/IBD: abdominal tenderness, perianal fistula, mouth ulcers, episcleritis, erythema nodosum

— Infectious: heart murmur (endocarditis), draining sinus tract (osteomyelitis), prosthetic joint warmth

— Malignancy: lymphadenopathy, hepatosplenomegaly, breast/testicular mass, rectal mass, occult stool

— CKD: uremic frost (rare), AV fistula, dialysis access, pruritus excoriations

— CHF: JVD, S3, crackles, peripheral edema, hepatic congestion

— Glossitis, angular cheilitis, koilonychia (spoon nails) → iron deficiency

— Subacute combined degeneration signs (lost proprioception, hyperreflexia, dementia) → B12

— Jaundice, scleral icterus, splenomegaly → hemolysis

— Petechiae, mucosal bleeding, ecchymoses → marrow failure or thrombocytopenia

— Calculate shock index (HR/SBP); >0.9 suggests volume loss

— Orthostatic vitals are mandatory if any bleeding suspicion

CCS pearl: On a CCS case with anemia and a chronic disease, the rectal exam with FOBT is a high-yield order that frequently changes the diagnosis. Skipping it costs management points when occult GI bleed is the true driver.

Board pearl: A flow murmur that resolves after correction of anemia is benign; a murmur that persists demands echo to evaluate for endocarditis as the underlying inflammatory driver.

General appearance and vitals:

Stigmata of underlying disease (focus the exam):

Findings that point AWAY from pure ACD:

Hemodynamic assessment:

Diagnostic Workup — Initial Labs

— Hgb typically 8–10 g/dL; MCV normal (75%) or low (25%)

— RDW: normal in pure ACD, elevated in IDA or mixed picture

— Smear: normocytic normochromic; no schistocytes, no spherocytes, no blasts

— Reticulocyte production index (RPI) <2 → hypoproliferative, consistent with ACD

— RPI >2 → think hemolysis or recent blood loss recovery

— Serum iron: ↓ (hepcidin sequesters iron)

— TIBC (transferrin): ↓ or normal (negative acute-phase reactant)

— Transferrin saturation (TSAT): low-normal to low (often 10–20%)

— Ferritin: ↑ or normal (acute-phase reactant; usually >100 ng/mL in ACD)

— sTfR (soluble transferrin receptor): normal (elevated in IDA)

— IDA: ↓iron, ↑TIBC, ↓TSAT (<16%), ↓ferritin (<30), ↑sTfR

— Ferritin 30–100 with chronic disease is the diagnostic gray zone → use sTfR/log ferritin index or trial of iron

— B12, folate — rule out macrocytic overlay (even with normal MCV, deficiency can mask)

— Creatinine/eGFR — CKD as driver; EPO deficiency dominates when eGFR <60

— TSH — hypothyroidism causes normocytic anemia

— LFTs — hepatic disease, alcohol

— CRP/ESR — confirm active inflammation

— LDH, haptoglobin, indirect bilirubin — exclude hemolysis

— Stool occult blood, urinalysis — screen for occult loss

Step 3 management: Order iron studies, retics, B12/folate, CRP, creatinine, TSH, and FOBT in one bundle at first encounter for any new anemia in a chronic disease patient. Sequential single-test ordering loses CCS efficiency points and delays diagnosis.

Board pearl: Ferritin >100 ng/mL with low TSAT virtually excludes pure iron deficiency; ferritin <30 ng/mL is diagnostic of iron deficiency regardless of inflammation status.

CBC with differential and peripheral smear is step one:

Reticulocyte count / index:

Iron studies — the discriminating test set:

Compare to iron deficiency anemia (IDA):

Additional initial labs:

Diagnostic Workup — Advanced or Confirmatory Studies

— Soluble transferrin receptor (sTfR) — elevated in IDA, normal in ACD

— sTfR/log ferritin index (Thomas plot):

— <1: pure ACD

— >2: ACD + iron deficiency (mixed)

— Reticulocyte hemoglobin content (CHr/Ret-He) <28 pg: early iron-deficient erythropoiesis even before ferritin drops

— Hepcidin levels: research/specialty use; low in IDA, high in ACD — not routine

— Pancytopenia, blasts on smear, or marrow infiltration suspected

— Diagnosis remains unclear after non-invasive workup

— Suspected MDS in elderly (refractory anemia, ringed sideroblasts)

— Findings in ACD: abundant storage iron in macrophages, reduced sideroblasts (iron trapped, can't be used)

— All men with IDA

— All postmenopausal women with IDA

— Premenopausal women with IDA out of proportion to menses or with GI symptoms

— CT chest/abdomen for occult malignancy

— Echocardiogram if endocarditis suspected

— HIV, HCV, TB screen if not done

— SPEP/UPEP/free light chains in older adults — rule out multiple myeloma (common ACD mimic)

Key distinction: Multiple myeloma classically presents as normocytic anemia with rouleaux, high ESR, renal dysfunction, hypercalcemia, bone pain — order SPEP/UPEP/serum free light chains in any patient >50 with unexplained normocytic anemia.

Board pearl: A bone marrow showing iron-laden macrophages but iron-poor erythroblasts is pathognomonic for the functional iron deficiency of ACD.

When initial workup is equivocal, especially ferritin 30–100 ng/mL in an inflamed patient:

Bone marrow biopsy — rarely needed for ACD diagnosis, indicated if:

Hemoglobin electrophoresis / HPLC — if microcytic with normal/high iron studies and family history → thalassemia trait

Endoscopy/colonoscopy — mandatory if iron deficiency is identified, especially:

Imaging/targeted disease workup based on suspected driver:

EPO level — useful in CKD or to assess EPO-resistance; normal-low in ACD relative to severity

Risk Stratification and First-Line Management Logic

— RA flare → optimize DMARD/biologic therapy (anti-IL-6 like tocilizumab uniquely improves ACD by suppressing hepcidin)

— IBD → induce remission with steroids, biologics, mesalamine

— Active infection (osteomyelitis, endocarditis, TB) → targeted antimicrobials

— Malignancy → definitive oncologic therapy

— CKD → optimize as below

— Most ACD resolves or improves significantly with disease control

— Hgb >10 g/dL, asymptomatic: treat underlying disease, monitor — no specific anemia therapy

— Hgb 8–10 g/dL, symptomatic (fatigue, dyspnea, angina): consider ESA ± iron repletion if appropriate

— Hgb <8 g/dL or hemodynamic compromise: transfuse, then investigate for second process (bleeding, hemolysis, marrow failure)

— Coexisting absolute iron deficiency (ferritin <100, TSAT <20%): iron repletion first — prefer IV iron if inflammation is active (oral absorption blocked by hepcidin)

— CKD-associated ACD with EPO deficiency: ESA (epoetin alfa, darbepoetin) per KDIGO when Hgb <10

— Chemotherapy-induced anemia: ESA acceptable for palliative-intent chemo when Hgb <10 (not in curative-intent or non-chemo cancer anemia — increases mortality/thrombosis)

— Functional iron deficiency on ESA: add IV iron to optimize response

— Hgb <7 g/dL: most hospitalized stable adults

— Hgb <8 g/dL: cardiac surgery, orthopedic surgery, preexisting CAD

— Symptomatic (active ischemia, hemodynamic instability): transfuse regardless

Step 3 management: Avoid the trap of transfusing every patient with Hgb 8–9 — restrictive transfusion is associated with lower mortality in most populations. Save blood for symptomatic patients or those with active bleeding.

Board pearl: ACD with Hgb consistently <8 g/dL should always prompt a search for an additional process — pure ACD rarely drops that low.

Treat the underlying disease first — this is the cornerstone:

Severity-based stratification:

Decision tree for adjunctive therapy:

Transfusion thresholds (restrictive strategy — AABB):

Pharmacotherapy — First-Line Drug Regimens

— Epoetin alfa: typical 50–100 units/kg SC three times weekly

— Darbepoetin alfa: longer half-life, 0.45 mcg/kg weekly or 0.75 mcg/kg q2 weeks

— Indications: CKD (eGFR <60 with Hgb <10 after iron repletion), chemotherapy-induced anemia (palliative chemo only), select MDS, zidovudine-treated HIV

— Target Hgb 10–11.5 g/dL; do NOT exceed 11.5–12 — overshooting causes stroke, MI, VTE, mortality (CHOIR, TREAT trials)

— Hold or reduce dose if Hgb >11; never administer if uncontrolled HTN or recent stroke/VTE

— Oral iron: ferrous sulfate 325 mg every other day (better absorption than daily dosing — Stoffel data) — works only when inflammation is mild and hepcidin not severely elevated

— IV iron: preferred in active inflammation, CKD, IBD, post-bariatric, ESA cotherapy

— Iron sucrose (Venofer): 100–200 mg per session, multiple doses

— Ferric gluconate: 125 mg per session

— Ferric carboxymaltose (Injectafer): 750 mg up to 2 doses — risk of hypophosphatemia

— Ferumoxytol, iron isomaltoside: single large-dose options

— Iron repletion goal: TSAT >20–30%, ferritin 100–500 ng/mL in CKD on ESA

— Tocilizumab (anti-IL-6R) directly suppresses hepcidin — uniquely improves anemia in RA, Castleman disease

— Anti-TNF agents (infliximab, adalimumab) improve ACD in IBD and RA

— Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs): roxadustat, daprodustat — oral, suppress hepcidin and stimulate endogenous EPO; approved for CKD-related anemia

— Empiric oral iron in active inflammation without confirmed deficiency

— ESAs in non-chemotherapy cancer anemia

— ESAs targeting normal Hgb levels

Board pearl: Ferric carboxymaltose causes symptomatic hypophosphatemia in up to 50% — check phosphate after repeated dosing, especially in IBD patients.

Step 3 management: Always iron-replete first, then initiate ESA. Treating with ESA alone when iron-deficient causes a poor response and unnecessary drug exposure.

Erythropoiesis-stimulating agents (ESAs):

Iron repletion — mandatory before/with ESA to prevent functional iron deficiency:

Targeted disease-modifying therapy:

Avoid:

Procedures and Expanded Pharmacology

— One unit pRBC raises Hgb ~1 g/dL in non-bleeding adult

— Restrictive thresholds (AABB 2023): transfuse at Hgb <7 (most patients), <8 (cardiac/orthopedic surgery, preexisting CVD), symptomatic patients regardless of Hgb

— Risks: TRALI, TACO, alloimmunization (especially relevant for chronically transfused patients with myelodysplasia, thalassemia, sickle cell)

— Iron overload is a concern in chronically transfused patients (each unit = ~200–250 mg iron); monitor ferritin, consider chelation (deferasirox, deferoxamine) when ferritin >1000–2500 or after ~20 lifetime units

— Pretest for hypersensitivity not required for modern formulations (low anaphylaxis risk)

— Test dose abandoned for ferric carboxymaltose, ferumoxytol

— Monitor BP and observe 30 minutes post-infusion

— Repeat iron studies 4–8 weeks after course completion

— AV fistula placement minimizes catheter-related blood loss (a major contributor to anemia in HD patients)

— Mechanism: stabilize HIF, increasing endogenous EPO and iron absorption

— Advantage: oral dosing, reduce hepcidin

— Risks: thrombosis, possible cancer/cardiovascular signals (still under monitoring)

— Use mainly in dialysis-dependent CKD

— Replete B12 and folate if deficient

— Vitamin C does not improve iron absorption clinically meaningfully — don't co-prescribe routinely

— Cluster labs, use pediatric tubes — iatrogenic blood loss can be 30–50 mL/day in ICU

CCS pearl: When ordering pRBC transfusion on CCS, also order post-transfusion CBC at 1 hour and 4–6 hours — failure to rise suggests bleeding or hemolysis; rise >1 g/dL/unit and stable confirms uncomplicated transfusion.

Board pearl: Hgb rising 0.5–1.0 g/dL within 2 weeks of ESA initiation indicates adequate response; less suggests iron-restricted erythropoiesis — re-check iron studies and supplement.

Red blood cell transfusion — symptomatic management, not corrective:

IV iron protocols — outpatient infusion center:

Dialysis access optimization in CKD-related ACD:

Bone marrow transplantation: reserved for MDS, severe aplastic anemia overlap — not for pure ACD

HIF-PHIs (roxadustat, daprodustat, vadadustat):

Vitamin/cofactor optimization:

Phlebotomy minimization in inpatients:

Special Populations — Elderly and Renal/Hepatic Impairment

— Anemia present in ~10% of community-dwelling adults >65, >20% over age 85

— One-third of elderly anemia is ACD/inflammation-driven, one-third nutritional (iron, B12, folate), one-third unexplained anemia of the elderly (UAE)

— Always rule out MDS (refractory anemia, dysplastic features, ring sideroblasts) — peripheral smear and SPEP/free light chains for myeloma

— Anemia in elderly is never normal — associated with increased falls, cognitive decline, hospitalization, mortality

— Use lower transfusion threshold (Hgb 8) if cardiac disease or symptomatic

— Multifactorial: EPO deficiency (dominant), hepcidin elevation, uremic toxin marrow suppression, shortened RBC lifespan, frequent blood loss (dialysis, labs)

— KDIGO targets:

— Initiate ESA when Hgb <10 g/dL (after iron repletion if needed)

— Target Hgb 10–11.5 g/dL — do not exceed 11.5

— Iron repletion goal: ferritin 100–500 (non-dialysis), 200–500 (dialysis); TSAT 20–30%

— IV iron preferred for dialysis patients

— HIF-PHIs are an oral alternative to ESAs

— Cirrhosis-related anemia is multifactorial: portal hypertensive bleeding, hypersplenism, folate deficiency (alcohol use), bone marrow suppression, hemolysis (spur cell), ACD from chronic inflammation

— Avoid IV iron overload — cirrhotics already at risk; check ferritin

— Transfuse to Hgb 7 (restrictive), avoid over-transfusion in variceal bleeding (worsens portal pressure)

— ESAs dosed by weight; no major hepatic adjustment

— IV iron generally renally safe but hold during active infection (iron promotes bacterial growth)

Step 3 management: In a CKD patient with new anemia, always check iron studies and replete iron before starting ESA — most "ESA failure" is unrecognized iron deficiency.

Board pearl: Unexplained anemia in an elderly patient despite negative iron, B12, folate, TSH, and SPEP → order bone marrow biopsy to evaluate for MDS, especially with persistent macrocytosis or cytopenias.

Elderly patients:

CKD (the prototypical ACD scenario):

Hepatic impairment:

Drug dosing considerations:

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Physiologic dilutional anemia is normal (Hgb floor ~11 g/dL T1/T3, 10.5 T2)

— True ACD in pregnancy is uncommon — pregnancy is not pro-inflammatory; suspect coexisting disease (SLE flare, chronic infection)

— Iron deficiency dominates pregnancy anemia — supplement 27 mg elemental iron daily, more if deficient

— ESAs: safe but rarely needed; consider for severe CKD-related anemia in pregnancy

— IV iron: avoid first trimester; preferred T2/T3 if oral fails

— Transfusion thresholds similar but consider fetal oxygenation

— ACD in children most often from juvenile idiopathic arthritis (JIA), IBD, chronic infection, malignancy, CKD

— Lead poisoning is a key pediatric mimic — microcytic anemia with basophilic stippling

— Always rule out iron deficiency (very common in toddlers due to cow's milk)

— ESAs used in pediatric CKD per KDIGO with similar targets

— Multifactorial: ACD from chronic immune activation, zidovudine (AZT) marrow suppression, opportunistic infection (MAC, parvovirus B19, CMV), malignancy (lymphoma, KS), nutritional

— Parvovirus B19 causes pure red cell aplasia with giant pronormoblasts — treat with IVIG

— ART itself improves anemia by reducing inflammation

— Chemotherapy-induced anemia (CIA): ESA only for palliative chemotherapy, target Hgb 10–11

— Use lowest dose to avoid transfusion

— Black-box warning: ESAs may shorten survival in some cancers — avoid in curative-intent therapy

— Anemia tracks disease activity; tocilizumab uniquely effective (IL-6 blockade reduces hepcidin)

— "Sports anemia" — dilutional from plasma volume expansion; not true anemia

— True iron deficiency common in endurance athletes (foot-strike hemolysis, GI loss)

Board pearl: A patient with sickle cell disease who suddenly develops a profound aplastic crisis (Hgb drop, reticulocytopenia) most likely has parvovirus B19 infection — treat supportively ± IVIG, isolate from pregnant contacts.

Step 3 management: Test for parvovirus B19 IgM/PCR in any immunocompromised patient (HIV, transplant, hemolytic anemia) with sudden reticulocytopenia.

Pregnancy:

Pediatrics:

HIV-associated anemia:

Cancer patients:

Autoimmune disease flares:

Athletes:

Complications and Adverse Outcomes

— Fatigue, decreased exercise capacity, decreased quality of life

— Worsening cardiovascular disease: angina, decompensated heart failure, demand ischemia

— Cognitive impairment in elderly; increased fall risk, fractures

— Increased perioperative morbidity and mortality; preop Hgb <10 strongly predicts adverse outcomes

— Prolonged hospital stays, increased readmissions, increased all-cause mortality independent of underlying disease severity

— ESA-associated risks (black-box warnings):

— Thromboembolism: VTE, stroke, MI — risk rises sharply with Hgb >11.5–12

— Hypertension exacerbation

— Pure red cell aplasia (PRCA) — rare antibody-mediated; suspect with sudden ESA resistance and reticulocytopenia

— Tumor progression in non-chemo cancer anemia

— IV iron risks:

— Anaphylaxis (rare with modern preparations)

— Hypophosphatemia (especially ferric carboxymaltose, repeated dosing)

— Hemosiderosis with chronic over-repletion

— Transfusion complications:

— TRALI, TACO (most common cause of transfusion-related mortality)

— Hemolytic reactions (ABO error), febrile non-hemolytic, allergic

— Alloimmunization in chronically transfused patients

— Transfusional iron overload in patients receiving >20 units lifetime → cardiomyopathy, hepatic fibrosis, endocrinopathy

— Continued inflammation perpetuates anemia, accelerates organ damage

— Missing occult malignancy or GI bleed delays curative intervention

Step 3 management: ESA-treated patient with sudden drop in Hgb and absent reticulocytes → stop ESA, screen for neutralizing antibodies (PRCA), transfuse as needed, consider immunosuppression. Do not switch to a different ESA — antibodies cross-react.

Board pearl: TACO (transfusion-associated circulatory overload) is the leading cause of transfusion-related death — restrict transfusion volume in elderly and CHF patients, give furosemide between units, transfuse slowly (over 3–4 hours per unit).

Direct anemia complications:

Complications from treatment:

Untreated underlying disease consequences:

When to Escalate Care — ICU, Consult, or Inpatient Triage

— Hemodynamic instability: SBP <90, HR >120, lactate >2 with anemia

— Active GI bleeding with hemodynamic compromise

— Severe symptomatic anemia (Hgb <6–7) with ongoing decompensation

— Acute coronary syndrome with Hgb <8 not responsive to single-unit transfusion

— Acute hemolytic transfusion reaction

— Hgb <7 with symptoms; <8 in patient with CAD

— New anemia with concern for active bleeding requiring monitoring

— Need for IV therapy (iron, antibiotics for underlying infection) that cannot be done outpatient

— Failure to thrive in elderly patient with new severe anemia

— Stable, mild-moderate anemia, no acute symptoms, known underlying chronic disease

— Iron infusion can be arranged at infusion center

— ESA initiation in CKD clinic

— Hematology: unexplained anemia despite workup, suspected MDS/myeloma/aplastic anemia, ESA failure, transfusion-dependent anemia, suspected PRCA

— Gastroenterology: confirmed iron deficiency requiring endoscopy/colonoscopy, IBD flare

— Nephrology: CKD-related ACD requiring ESA management

— Oncology: any new malignancy diagnosis, chemo-induced anemia management

— Rheumatology: active autoimmune disease driving anemia

— Infectious disease: suspected endocarditis, osteomyelitis, TB, HIV

CCS pearl: On a CCS case with Hgb 6.5 and SBP 88 from suspected GI bleed, simultaneously order: 2 large-bore IVs, type & cross 2 units pRBC, IV PPI, CBC q4–6h, transfer to ICU/step-down, and GI consult for emergent endoscopy. Sequential ordering loses time and points.

Step 3 management: Mild ACD with Hgb 10 in a stable RA patient can be managed entirely in primary care — no hematology consult needed if workup is unrevealing and disease control is in progress.

ICU admission criteria:

Inpatient (floor) admission criteria:

Outpatient management appropriate when:

Consultation triggers:

Transfusion service consultation: for chronically transfused patients, alloimmunization, suspected delayed hemolytic transfusion reaction

Key Differentials — Same-Category Causes (Other Microcytic/Normocytic Anemias)

— Microcytic, hypochromic, ↑RDW

— ↓ferritin (<30), ↑TIBC, ↑sTfR, TSAT <16%

— Always investigate for source of blood loss — colonoscopy/EGD in men and postmenopausal women

— Coexists with ACD in ~20% of inflamed patients (mixed picture)

— Microcytic with disproportionately low MCV (often <70) and normal-to-elevated RBC count

— Mentzer index (MCV/RBC) <13 suggests thalassemia, >13 suggests IDA

— Normal iron studies, normal RDW

— Hgb electrophoresis: ↑HbA2 in β-thalassemia trait

— Inherited (X-linked, ALAS2 mutation) or acquired (alcohol, lead, isoniazid, copper deficiency, MDS)

— High serum iron and ferritin, low TIBC; ringed sideroblasts on marrow Prussian blue stain

— Microcytic anemia, basophilic stippling, abdominal pain, peripheral neuropathy

— Elevated blood lead level; classic in children with old paint exposure, adult occupational

— Considered a form of ACD but EPO deficiency dominates

— Normocytic, low retics, normal iron studies usually

— Treat with ESA + iron when Hgb <10

— Normocytic, mild, no identifiable cause after thorough workup

— Diagnosis of exclusion — must exclude MDS, myeloma

— Hypothyroidism, hypogonadism, adrenal insufficiency — normocytic anemia that resolves with hormone replacement

Key distinction:

— IDA: ↑TIBC, ↓ferritin, ↑sTfR, ↑RDW

— ACD: ↓TIBC, ↑ferritin, normal sTfR, normal RDW

— Mixed ACD+IDA: ↑sTfR with ferritin 30–100 and TSAT <20%

— Thalassemia: normal iron studies, low Mentzer index, abnormal electrophoresis

Board pearl: A patient with ferritin 50 ng/mL, TSAT 12%, and active RA — order sTfR or trial a course of iron. If retics rise and Hgb improves, coexisting iron deficiency was operative and GI workup is mandatory.

Iron deficiency anemia (IDA) — the principal differential:

Thalassemia trait (α or β):

Sideroblastic anemia:

Lead poisoning:

Anemia of chronic kidney disease:

Anemia of aging (unexplained anemia of the elderly):

Endocrine-related anemia:

Key Differentials — Other-Category Causes

— B12 deficiency: hypersegmented neutrophils, neurologic findings, methylmalonic acid elevated; pernicious anemia, ileal disease, metformin, PPIs

— Folate deficiency: similar smear, no neuro findings; alcoholism, malnutrition, methotrexate

— MDS: refractory cytopenias, dysplasia, blasts on smear

— Drug-induced: hydroxyurea, AZT, chemotherapy, sulfa

— Reticulocytosis: hemolysis or hemorrhage producing immature large RBCs

— Hypothyroidism, liver disease, alcohol: mild macrocytosis

— Intrinsic: G6PD deficiency, hereditary spherocytosis, sickle cell, thalassemia major, PNH

— Extrinsic: autoimmune (warm IgG vs cold IgM), microangiopathic (TTP, HUS, DIC, HELLP), mechanical (prosthetic valve), drug-induced

— Lab clues: ↑LDH, ↑indirect bilirubin, ↓haptoglobin, ↑reticulocytes, abnormal smear (spherocytes, schistocytes, bite cells)

— Direct antiglobulin test (Coombs) for autoimmune

— Aplastic anemia: pancytopenia, hypocellular marrow; idiopathic, drug, viral, radiation

— MDS: dysplastic marrow, often elderly

— Marrow infiltration: lymphoma, metastatic cancer (breast, prostate, lung) — leukoerythroblastic smear with teardrop cells, nucleated RBCs, immature myeloid forms

— Multiple myeloma: rouleaux, M-spike, hypercalcemia, renal failure

— Initial Hgb may be normal; equilibration takes 24–48 hours

— Reticulocytosis appears in 3–5 days

— Methotrexate, AZT, linezolid, chloramphenicol — marrow suppression

— Penicillins, cephalosporins, methyldopa — immune hemolysis

— Ribavirin — hemolysis

Step 3 management: Always check reticulocyte count early — distinguishes hypoproliferative (ACD, IDA, marrow failure, CKD) from hyperproliferative (hemolysis, hemorrhage). This single test redirects the entire workup.

Board pearl: A normocytic anemia with leukoerythroblastic smear (nucleated RBCs, teardrops, myelocytes) means marrow infiltration until proven otherwise — order bone marrow biopsy and search for primary malignancy.

Macrocytic anemias (MCV >100):

Hemolytic anemias:

Marrow failure/infiltration:

Acute blood loss anemia:

Anemia from medications:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Iron supplements (oral if tolerated, IV course scheduled if needed)

— ESA prescription with clear administration instructions, target Hgb 10–11.5, NOT higher

— B12/folate replacement if coexisting deficiency

— Disease-modifying therapy for underlying inflammatory disease (DMARDs, biologics, ART, antimicrobials)

— PPI gastroprotection if on NSAIDs/steroids to prevent GI bleed compounding anemia

— Stop/avoid contributing drugs where possible (unnecessary NSAIDs, AZT alternatives)

— RA: target low disease activity by DAS28 or CDAI

— IBD: maintain remission with mesalamine/biologics

— CKD: BP control (<130/80), ACEi/ARB, glycemic control, avoid nephrotoxins

— CHF: GDMT (ARNi/ACEi, β-blocker, MRA, SGLT2i)

— HIV: ART adherence to maintain virologic suppression

— Iron-rich diet (red meat, beans, fortified cereals) — supplement still usually needed

— Avoid excessive tea/coffee with iron supplements (impair absorption)

— Limit alcohol — worsens nutritional deficiency, GI bleeding, marrow suppression

— Smoking cessation — reduces inflammatory burden

— Influenza annually, COVID, pneumococcal, zoster, HBV (especially CKD, IBD, on immunosuppressants)

— Reduces inflammatory drivers from preventable infections

— Age-appropriate cancer screening (colonoscopy, mammography, cervical, lung CT for eligible smokers, PSA discussion)

— Particularly important since malignancy can drive ACD

— Preoperative anemia is a major modifiable risk factor — refer to Patient Blood Management clinic if Hgb <12 preop; treat iron deficiency 4–6 weeks before elective surgery

Step 3 management: A patient discharged after IV iron course for IBD-related ACD needs follow-up CBC and iron studies in 4 weeks, ferritin/TSAT goal achieved before considering next dose. Plan IBD maintenance therapy at discharge — don't leave inflammatory driver untreated.

Board pearl: Preoperative correction of anemia 4–6 weeks before elective surgery with IV iron ± ESA reduces transfusion requirements and 30-day mortality.

Discharge medication reconciliation:

Underlying disease optimization (the most important long-term step):

Lifestyle and nutritional counseling:

Vaccinations:

Screening and prevention:

Surgical/perioperative planning:

Follow-Up, Monitoring Parameters, and Counseling

— CBC at 2–4 weeks: expect Hgb rise of 0.5–1 g/dL with effective iron repletion or ESA

— Iron studies at 4–8 weeks after IV iron course

— CBC monthly while titrating ESA dose; q3 months when stable

— Reticulocyte count if response is inadequate

— Hgb weekly during titration, then monthly

— Hold ESA if Hgb >11.5–12 to avoid cardiovascular harm

— Check BP at every visit

— Monitor for PRCA: sudden Hgb drop with retics <10,000 → anti-EPO antibody testing

— Re-evaluate iron status every 1–3 months

— Annual CBC, iron studies, B12/folate if at risk

— Disease-specific monitoring: CRP/ESR for RA, fecal calprotectin for IBD, creatinine for CKD

— Repeat workup if anemia worsens despite stable disease — search for new process (occult bleed, malignancy, medication effect)

— Set realistic expectations: ACD improves with disease control but may not fully normalize

— Iron supplements: take every other day, on empty stomach if tolerated, expect dark stools (don't confuse with melena), constipation common

— ESA injections: self-administration training, sharps disposal, refrigeration

— Reportable symptoms: chest pain, severe headache, leg swelling, neurologic changes (ESA-related stroke/MI/VTE)

— Bleeding precautions if also anticoagulated

— Gradual return to activity as Hgb improves

— Address deconditioning, especially in elderly

— Cardiac rehab eligibility if CAD/CHF coexists

Step 3 management: For a CKD patient on darbepoetin, monthly Hgb monitoring with dose adjustment to maintain 10–11.5 g/dL is the standard — overshooting to 13+ violates KDIGO and FDA guidance and increases stroke/MI risk.

CCS pearl: Schedule follow-up clinic visit at 2 weeks after starting iron or ESA therapy on a CCS case — earlier checks lose points (premature) but later checks miss non-responders. The 2–4 week window is the sweet spot.

Initial follow-up after starting therapy:

ESA monitoring (KDIGO and FDA):

Long-term surveillance:

Counseling points:

Rehabilitation:

Ethical, Legal, and Patient Safety Considerations

— Discuss benefits, alternatives, and risks: infection (HIV ~1:1.5M, HCV ~1:1M, HBV ~1:1M, bacterial sepsis, CMV), TRALI, TACO, hemolytic reactions, alloimmunization

— Document discussion clearly in the chart

— Jehovah's Witnesses refuse allogeneic blood products: respect autonomy, discuss acceptable alternatives (autologous techniques, EPO, IV iron, cell salvage, hemoglobin-based oxygen carriers in trial settings); blood fractions vary by individual

— Minor children of Jehovah's Witness parents: courts may override refusal for life-threatening anemia — involve hospital ethics and legal counsel

— Severely anemic patients with cerebral hypoperfusion may have impaired capacity — assess carefully

— Use surrogate decision-maker per state hierarchy when capacity lacking

— Medication reconciliation at discharge is a Joint Commission National Patient Safety Goal — verify iron, ESA, B12, folate, anticoagulants, NSAIDs

— Clearly communicate target Hgb, ESA dosing, and monitoring schedule to PCP and infusion center

— High-risk handoff scenario: discharging patient on ESA without arranged outpatient monitoring → preventable harm from Hgb overshoot

— Use teach-back to confirm patient understanding of iron schedule, ESA injection technique

— Document discussion of thrombotic risks and tumor progression risk before initiating

— REMS program (APPRISE) historically required for oncology ESA prescribing

— Lead poisoning is reportable in most states — investigate housing, notify health department

— Occupational anemia (benzene, lead): workers' compensation, OSHA reporting

— Iron deficiency and ACD disproportionately affect low-income, minority, and immigrant populations — screen and address food insecurity

— Cost of ESAs and IV iron significant — prior authorization commonly needed; advocate for patient access

Board pearl: A Jehovah's Witness with Hgb 5.5 from chronic blood loss who refuses transfusion: maximize IV iron + high-dose ESA, treat underlying source, accept higher mortality risk only if patient has capacity — document carefully.

Step 3 management: Always confirm outpatient follow-up appointment scheduled before discharging an ESA-treated patient — unmonitored ESA therapy is a sentinel safety event.

Informed consent for transfusion:

Capacity and surrogate decision-making:

Transition-of-care safety:

ESA black-box warnings — disclosure:

Mandatory reporting and public health:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: Trial of oral iron in equivocal ACD — if reticulocytosis and Hgb rise occur within 1–2 weeks, true iron deficiency was present and warrants source workup.

Key distinction: ACD with Hgb <8, blasts on smear, or pancytopenia is not just ACD — pursue marrow biopsy.

Hepcidin is the master regulator — produced by liver, induced by IL-6, blocks ferroportin → traps iron

Ferroportin is the only known cellular iron exporter; located on enterocytes, macrophages, hepatocytes

Ferritin is an acute-phase reactant — interpret with CRP/ESR context

TIBC (transferrin) is a negative acute-phase reactant — low in ACD, high in IDA

Mentzer index = MCV/RBC: <13 thalassemia, >13 IDA

Reticulocyte production index (RPI) <2 = hypoproliferative; >2 = appropriate response

Ferritin <30 = iron deficiency, regardless of inflammation

Ferritin >100 with low TSAT = ACD, not pure IDA

Tocilizumab uniquely improves anemia by suppressing IL-6 → hepcidin

Parvovirus B19 → pure red cell aplasia in immunocompromised and chronic hemolytic anemia (sickle cell, hereditary spherocytosis) — giant pronormoblasts

HIF-PHIs (roxadustat) — newer oral agents for CKD anemia, increase EPO and decrease hepcidin

Ferric carboxymaltose → symptomatic hypophosphatemia

Restrictive transfusion threshold: Hgb <7 (most), <8 (cardiac/orthopedic, CAD)

ESA target Hgb: 10–11.5, never >12 — increased VTE/MI/stroke

Anemia of CKD: EPO deficiency dominant, treat with ESA + iron when Hgb <10

MDS is the classic mimic in elderly — order bone marrow if unexplained

Multiple myeloma is the classic mimic with rouleaux, hypercalcemia, renal failure — order SPEP/UPEP/light chains

Sickle cell + sudden aplastic crisis → parvovirus B19

AZT-induced anemia → switch ART agents

Lead poisoning → microcytic anemia with basophilic stippling, abdominal pain

Methotrexate → macrocytic anemia, folate-responsive

Sideroblastic → ringed sideroblasts on Prussian blue

Stoffel data: every-other-day oral iron dosing improves absorption vs daily

Iron infusion premedication: not routinely required for modern IV iron preparations

TACO > TRALI as cause of transfusion mortality currently

Spur cell anemia in cirrhosis from cholesterol-loaded membranes

Anemia of aging is a diagnosis of exclusion — always rule out MDS, myeloma

Board Question Stem Patterns

— 55F with seropositive RA on methotrexate has Hgb 9.8, MCV 84, ↓iron, ↓TIBC, ↑ferritin → ACD. Best initial step: optimize RA control, ± consider tocilizumab. Do not transfuse, do not start oral iron empirically.

— 62M with Crohn's disease, Hgb 9.0, MCV 78, ferritin 65, TSAT 14% → mixed ACD + IDA. Next step: colonoscopy + IV iron (oral poorly absorbed in active inflammation).

— 70F with eGFR 22, Hgb 9.2, normal iron studies → CKD-related ACD. Next: iron repletion (target ferritin >100, TSAT >20%), then ESA if Hgb still <10. Target Hgb 10–11.5.

— 78M with Hgb 9.5, MCV 100, normal iron/B12/folate/TSH/SPEP, persistent → bone marrow biopsy for MDS.

— 68F with normocytic anemia, back pain, Cr 2.1, Ca 11.2, rouleaux → SPEP/UPEP/serum free light chains, not iron studies. Diagnosis: multiple myeloma.

— Patient with sickle cell trait/disease or hereditary spherocytosis presents with sudden Hgb drop and reticulocytopenia → parvovirus B19 aplastic crisis. Treat: transfusion ± IVIG; isolate from pregnant contacts.

— CKD patient on epoetin titrated to Hgb 13 develops stroke → ESA overdosed; target should have been 10–11.5.

— Severe anemia, refuses transfusion → respect autonomy if capable adult; maximize IV iron and ESA, treat source.

— Patient receives ferric carboxymaltose, develops bone pain and weakness, phosphate 1.4 → iron-induced hypophosphatemia; replete phosphate, switch formulation.

— IVDU with normocytic anemia, fever, new murmur → ACD from infective endocarditis; treat with antibiotics, anemia resolves.

Step 3 management trap to avoid: Reflexive iron supplementation in a patient with high ferritin and low TIBC — this is ACD, not IDA. Iron will not help and may worsen iron overload over time.

Board pearl: When the stem gives you chronic inflammatory disease + mild normocytic anemia + ↑ferritin + ↓TIBC, the answer is almost always "treat the underlying disease."

Classic stem 1 — RA with anemia:

Classic stem 2 — Mixed picture:

Classic stem 3 — CKD anemia:

Classic stem 4 — Elderly unexplained anemia:

Classic stem 5 — Myeloma mimic:

Classic stem 6 — Parvovirus crisis:

Classic stem 7 — ESA harm:

Classic stem 8 — Jehovah's Witness:

Classic stem 9 — Hypophosphatemia after iron:

Classic stem 10 — Endocarditis driver:

One-Line Recap

Anemia of chronic disease is a hepcidin-driven, iron-sequestering, hypoproliferative anemia (low iron, low TIBC, high/normal ferritin) that is managed first and foremost by treating the underlying inflammatory, infectious, malignant, or renal driver — with iron repletion, ESAs, and transfusion reserved for selected refractory or symptomatic cases.

Board pearl: The single most powerful intervention in anemia of chronic disease is control of the underlying inflammatory driver — pharmacologic anemia correction is adjunctive, not primary.

Step 3 management bottom line: ACD is the most common anemia in hospitalized patients; don't reflexively transfuse, don't reflexively start iron, don't push ESAs to normal Hgb — treat the disease, replete deficiencies that are real, and follow restrictive evidence-based thresholds.

Diagnostic signature: normocytic (sometimes microcytic), low retics, ↓iron, ↓TIBC, ↑ferritin, normal sTfR — contrasted with IDA (↑TIBC, ↓ferritin, ↑sTfR)

Hgb floor: pure ACD rarely drops Hgb <8 — if it does, look for a second process (occult bleed, hemolysis, marrow failure, mixed IDA)

Treatment hierarchy: (1) treat underlying disease — anti-IL-6 (tocilizumab) uniquely effective; (2) replete iron, IV preferred in active inflammation; (3) ESA if Hgb <10 in CKD or palliative chemo, target 10–11.5 g/dL, never >12; (4) transfuse restrictively (Hgb <7 most, <8 cardiac/orthopedic)

High-yield mimics to always rule out: multiple myeloma (SPEP/light chains), MDS (bone marrow), occult GI bleed (colonoscopy/EGD), parvovirus B19 in immunocompromised/hemolytic patients, lead in children, thalassemia (Mentzer index, electrophoresis)

Step 3 mantra: Workup the underlying disease, replete iron before ESA, monitor Hgb monthly, never overshoot, coordinate outpatient follow-up, and screen for concurrent processes whenever anemia is severe or refractory